L M Ramondetta

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Treatment of uterine papillary serous carcinoma with paclitaxel
    L Ramondetta
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    Gynecol Oncol 82:156-61. 2001
  2. ncbi request reprint Mixed choriocarcinoma in a postmenopausal patient
    L M Ramondetta
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Gynecol Cancer 12:312-6. 2002
  3. ncbi request reprint Mentorship and productivity among gynecologic oncology fellows
    Lois M Ramondetta
    University of Texas M D Anderson Cancer Center, Department of Gynecologic Oncology, Houston, Texas 77030 4009, USA
    J Cancer Educ 18:15-9. 2003
  4. ncbi request reprint A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets
    Lois M Ramondetta
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 90:529-36. 2003
  5. ncbi request reprint Metastatic uterine papillary serous carcinoma to the pericardium
    P T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gynecol Oncol 83:135-7. 2001
  6. ncbi request reprint Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study
    L M Ramondetta
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Gynecol Cancer 14:580-8. 2004
  7. ncbi request reprint Spirituality in gynecological oncology: a review
    L M Ramondetta
    Department of Gynecologic Oncology, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Int J Gynecol Cancer 14:183-201. 2004
  8. ncbi request reprint Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy
    B M Slomovitz
    Department of Oncology, Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 15:510-6. 2005
  9. ncbi request reprint Clinical challenges presented by three simultaneous solid tumors
    Y G Lin
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Division of Gynecologic Oncology, Lyndon Baines Johnson General Hospital, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:1159-63. 2006
  10. ncbi request reprint In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, P O Box 301439 UNIT 1362, Houston, TX 77230 1439, USA
    Cancer Chemother Pharmacol 62:51-8. 2008

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Treatment of uterine papillary serous carcinoma with paclitaxel
    L Ramondetta
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, 77030, USA
    Gynecol Oncol 82:156-61. 2001
    ..The aim of this study was to determine the effectiveness and toxicity of monthly treatment with intravenous paclitaxel for women with advanced or recurrent uterine papillary serous carcinoma (UPSC)...
  2. ncbi request reprint Mixed choriocarcinoma in a postmenopausal patient
    L M Ramondetta
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Gynecol Cancer 12:312-6. 2002
    ..This case reconfirms the deceptive presentation of the "great masquerader"...
  3. ncbi request reprint Mentorship and productivity among gynecologic oncology fellows
    Lois M Ramondetta
    University of Texas M D Anderson Cancer Center, Department of Gynecologic Oncology, Houston, Texas 77030 4009, USA
    J Cancer Educ 18:15-9. 2003
    ..To identify factors that enable gynecologic oncology fellows to achieve goals set by the American Board of Obstetrics and Gynecology (ABOG)...
  4. ncbi request reprint A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets
    Lois M Ramondetta
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 90:529-36. 2003
    ..The aim of this study was to determine the efficacy of cisplatin, ifosfamide, and mesna in uterine malignant mixed müllerian tumor (MMMT) and to evaluate the expression of clinically relevant molecular markers...
  5. ncbi request reprint Metastatic uterine papillary serous carcinoma to the pericardium
    P T Ramirez
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Gynecol Oncol 83:135-7. 2001
    ..Uterine papillary serous carcinoma is an aggressive tumor with a high propensity for distant spread. Metastases to the heart or pericardium are rare in gynecologic malignancies and usually fatal...
  6. ncbi request reprint Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study
    L M Ramondetta
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Gynecol Cancer 14:580-8. 2004
    ..Expanding our understanding of what motivates GOs to recommend continued treatment over palliation is important for preserving informed patient-motivated end-of-life decisions...
  7. ncbi request reprint Spirituality in gynecological oncology: a review
    L M Ramondetta
    Department of Gynecologic Oncology, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Int J Gynecol Cancer 14:183-201. 2004
    ....
  8. ncbi request reprint Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy
    B M Slomovitz
    Department of Oncology, Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 15:510-6. 2005
    ..Future prospective clinical trials should consider subclassifying patients with stage IIIA disease to better evaluate the role of adjuvant therapy...
  9. ncbi request reprint Clinical challenges presented by three simultaneous solid tumors
    Y G Lin
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Division of Gynecologic Oncology, Lyndon Baines Johnson General Hospital, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:1159-63. 2006
    ..Simultaneous tumors are rare, and their management can be challenging. The simultaneous presentation of cervical carcinoma, renal cell carcinoma, and appendiceal carcinoma has not been previously described...
  10. ncbi request reprint In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
    Judith A Smith
    Department of Gynecologic Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, P O Box 301439 UNIT 1362, Houston, TX 77230 1439, USA
    Cancer Chemother Pharmacol 62:51-8. 2008
    ..In addition, the effect of gefitinib on the expression of ATP-binding cassette (ABC) transport proteins was evaluated...
  11. ncbi request reprint From technician to professional: integrating spirituality into medical practice
    Chad F Slieper
    Clinical Ethics Service, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Bioeth 7:26-7. 2007
  12. ncbi request reprint Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy
    Lois M Ramondetta
    Department of Obstetrics and Gynecology, The University of Texas Lyndon Baines Johnson General Hospital, Houston, TX 77230, USA
    Gynecol Oncol 103:547-53. 2006
    ..To document obstacles to completing outpatient treatment faced by indigent patients with cervical cancer and compare treatment costs...
  13. ncbi request reprint Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    Gynecol Oncol 103:518-22. 2006
    ..To evaluate the mechanism that gemcitabine modulates cisplatin drug resistance in endometrial cancer cell lines...
  14. ncbi request reprint Active coping mediates the association between religion/spirituality and functional well-being in ovarian cancer
    Andrea L Canada
    Department of Behavioral Science, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 99:S125. 2005
  15. ncbi request reprint Active coping mediates the association between religion/spirituality and quality of life in ovarian cancer
    Andrea L Canada
    Department of Behavioral Science, The University of Texas M D Anderson Cancer Center Unit 1330, PO Box 310439, Houston, TX 77230 1439, USA
    Gynecol Oncol 101:102-7. 2006
    ..This study investigated the role of religion/spirituality (R/S) and coping in quality of life (QOL) in 129 women immediately prior to a course of adjuvant chemotherapy for ovarian cancer...
  16. ncbi request reprint Practice patterns of SGO members for stage IIIA endometrial cancer
    Christine M Lee
    Department of Gynecologic Oncology, Division of Surgery, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Gynecol Oncol 98:77-83. 2005
    ..The aim of this study was to survey the Society of Gynecologic Oncologists (SGO) members and fellows about their approach to the treatment of patients with stage IIIA endometrial cancer...
  17. ncbi request reprint Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas
    Jimmy J Caudell
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Appl Immunohistochem Mol Morphol 13:167-70. 2005
    ..These results indicate that many uterine sarcomas express 1 or more of the kinases targeted by imatinib mesylate and that further investigation of imatinib as a therapy for uterine sarcomas is warranted...
  18. ncbi request reprint Eleven years: the long and winding road
    Lois M Ramondetta
    Gynecol Oncol 107:166-8. 2007
  19. ncbi request reprint In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines
    Marisa A Navo
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230, USA
    Cancer Chemother Pharmacol 62:483-9. 2008
    ..To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines...
  20. ncbi request reprint An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines
    Judith A Smith
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 92:314-9. 2004
    ..To determine the cytotoxic activity of gemcitabine on a panel of endometrial cancer cell lines and to determine if the addition of platinum agents enhanced this activity...
  21. ncbi request reprint Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome
    Michael Callister
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 58:786-96. 2004
    ..To determine the survival outcomes, prognostic factors, and patterns of failure in patients with malignant mixed Müllerian tumor (MMMT) of the uterus...
  22. ncbi request reprint Spirituality and religion in the "art of dying"
    Lois M Ramondetta
    Department of Gynecologic Oncology, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:4460-2. 2003
  23. ncbi request reprint Use of a vacuum-assisted closure device in the treatment of recurrent Paget's disease of the vulva
    Hyun S Shvartsman
    Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Obstet Gynecol 102:1163-6. 2003
    ..Paget's disease of the vulva is a rare malignancy for which common recurrence is related to inadequate surgical margins. Excision with adequate surgical margins might leave a large defect that does not readily heal...
  24. ncbi request reprint Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium
    Francisco J Orejuela
    Department of Obstetrics, Gynecology and Reproductive Sciences, The University of Texas Health Science Center, Houston, TX 77025, USA
    Gynecol Oncol 97:483-8. 2005
    ..To determine whether cyclooxygenase-2 (COX-2) expression is seen in endometrial cancer, endometrial hyperplasia, and normal endometria and whether it correlates with expression of estrogen and progesterone receptors...
  25. ncbi request reprint The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors
    Jubilee Brown
    Department of Gynecologic Oncology, Unit 440, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 97:489-96. 2005
    ..We compared the efficacy and side effects of taxanes, with or without platinum, to bleomycin, etoposide, and cisplatin (BEP) in treating sex cord-stromal ovarian tumors...
  26. doi request reprint Social factors affecting treatment of cervical cancer: ethical issues and policy implications
    Shannon N Westin
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Obstet Gynecol 111:747-51. 2008
    ..In this paper, we report a tragic case where social factors affected the outcome of a single mother with advanced cervical cancer...
  27. ncbi request reprint Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment
    Mylin A Torres
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 70:118-25. 2008
    ..To compare the treatment and outcomes of cervical cancer patients treated with concurrent chemoradiotherapy (CT-RT) in a multi-institutional trial or as standard care...
  28. ncbi request reprint Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 91:463-9. 2003
    ..The identified characteristics were then correlated with overall survival (OS)...
  29. ncbi request reprint Adult granulosa cell tumors of the ovary in two first-degree relatives
    Tobey A Stevens
    Department of Obstetrics, Gynecology, and Reproductive Medicine, The University of Texas Health Science Center at Houston Medical School, Houston, TX 77030, USA
    Gynecol Oncol 98:502-5. 2005
    ..Known inherited mutations are responsible for approximately 10% of all epithelial ovarian cancers; however, prior to this report, sex cord-stromal ovarian tumors had not been documented in related females...
  30. ncbi request reprint Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix
    Alfred D Jenkins
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Unit 440, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 97:840-4. 2005
    ..To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer...
  31. ncbi request reprint PTEN expression in tamoxifen-associated endometrial cancers
    David Holtz
    Thomas Jefferson University, 111S 11th Street, 620 Gibbon Building, Department of Obstetrics and Gynecology, Philadelphia, PA 19107, USA
    Anticancer Res 22:2945-8. 2002
    ..PTEN, a tumor suppressor gene, is altered in low-grade endometrial carcinoma. This study evaluates PTEN immunohistochemical (IHC) expression in tamoxifen-associated endometrial cancers...
  32. ncbi request reprint Expression of imatinib mesylate-targeted kinases in endometrial carcinoma
    Brian M Slomovitz
    Department of Gynecologic Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Gynecol Oncol 95:32-6. 2004
    ..To determine whether imatinib mesylate could be a potentially useful agent in the treatment of endometrial cancer, we assessed the expressions of Abl, c-Kit, and PDGFR in both primary and recurrent endometrial carcinoma...
  33. doi request reprint Comparison of chemotherapy education and patient preferences in community versus academic gynecology oncology clinics
    Kellie L Jones
    Division of Pharmacy, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Oncol Pharm Pract 14:31-6. 2008
    ..To evaluate and compare patients' preferences in receiving chemotherapy education from health care teams in community versus academic clinics...